ArticleFrontiers in microbiology2021
Molecular Epidemiology of Carbapenem-Resistant
Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Resistance ofPathogens (Basel, Switzerland) · 2025Pooled it
- Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis.PloS one · 2024Pooled it
- Study Protocol for Genomic Epidemiology Investigation of Intensive Care Unit Patient Colonization by Antimicrobial-Resistant ESKAPE Pathogens.Methods and protocols · 2025Article
- Genomic insights into ST85 and ST158 belonging to recently emerged global clones of multidrug-resistant Acinetobacter baumannii isolates from Egypt: in vitro assessment of repurposed drug-antibiotic combinations.Annals of clinical microbiology and antimicrobials · 2025Article
- Global emergence ofMicrobial genomics · 2025Article
- Filamentous prophages in the genomes of Acinetobacter baumannii from egypt: impact on biofilm formation and the potential to induce enterotoxicity.BMC microbiology · 2025Article
- Comparative genomics of Acinetobacter baumannii from Egyptian healthcare settings reveals high-risk clones and resistance gene mobilization.BMC infectious diseases · 2025Article
- Comprehensive molecular epidemiology of Acinetobacter baumannii from diverse sources in Nigeria.BMC microbiology · 2025Article
- Impact of ISFrontiers in microbiology · 2025Article
- Article
- Genomic Landscape Reveals Chromosomally-Mediated Antimicrobial Resistome and Virulome of a High-Risk International Clone IIGlobal health, epidemiology and genomics · 2024Article
- Handwashing sinks as reservoirs of carbapenem-resistantFrontiers in public health · 2024Article
- Molecular Epidemiology and Genetic Characterization of Carbapenem-ResistantInfection and drug resistance · 2024Article
- International Clones of High Risk of Acinetobacter Baumannii-Definitions, History, Properties and Perspectives.Microorganisms · 2023Review
- Endemicity and diversification of carbapenem-resistantThe Lancet regional health. Western Pacific · 2023Article
- Article
- Article
- Global Epidemiology and Mechanisms of Resistance of Acinetobacter baumannii-calcoaceticus Complex.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Phenotypic and Molecular Characteristics of Carbapenem-ResistantMicroorganisms · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.